Real-world evidence is becoming increasingly important. New guidance from Health Canada and the Canadian Agency for Drugs and Technologies in Health shares how it can be best used.
Systematic review and meta-analysis finds that patients using biosimilars have equivalent clinical responses and functional capacity compared with those using reference biologic drugs.
The ministry says that, by working with psychiatrists, neuropsychologists and occupational therapists, a patient can grasp their new needs and limitations.